

## SCGE Phase 2 Publication Policy (May 24, 2024)

### **A. Publications**

One parameter of SCGE success will be the number and quality of its publications and presentations. The SCGE Translational Coordination and Dissemination Center (TCDC) will oversee the activities set out herein on behalf of the SCGE Steering Committee, and report to it. Changes to the policy described herein must be approved by the SCGE Steering Committee. The publication policy applies to publications for which the work supporting that publication is the product of NIH SCGE funding.

#### **A.1. Scope**

- A. To provide timely input to the SCGE TCDC of all SCGE consortium presentations, abstracts, preprints (if applicable), and publications, including consortium, collaborative, and individual project publications.
- B. The SCGE TCDC is responsible for tracking of activities and materials, including manuscript submissions of consortium and collaborative manuscripts, acceptance of all NIH SCGE-funded publications, and SCGE presentations.

#### **A.2. SCGE Manuscript Types**

- A. Consortium – represent major, cross-project publications (e.g., marker/white paper, SCGE data trends analysis).
- B. Collaborative – represent cross-project publications involving a small number of SCGE projects (e.g., experimental protocol development, new methods, research outcomes, review/commentary articles). Policies below describing manuscript proposals and their pre-submission review by the consortium (e.g., see section A.3.1 below) **do not** apply to this category.
- C. Individual project– represent publications of new methods, protocols, research outcomes, or reviews/commentaries driven by a single project. Policies below describing manuscript proposals and their pre-submission review by the consortium (e.g., see section A.3.1. below) **do not** apply to this category; publications or research results from individual projects/centers will be at the discretion of the PIs, as is generally the case for NIH-funded research.

#### **A.3. SCGE Manuscript Guidelines (Consortium, Collaborative and Individual project)**

- A. It is encouraged although not mandated that manuscripts be shared with the public via an appropriate public preprint server (e.g., *bioRxiv*, *arXiv*, *ChemRxiv*) prior to or concurrent with the

time of submission to a journal. Authors are requested to notify the TCDC of any SCGE bioRxiv postings so that such manuscripts can be included in the SCGE *bioRxiv* channel.

- B. All SCGE manuscripts should acknowledge the SCGE Consortium. The Acknowledgements should include a statement such as “This work was supported by the National Institutes of Health (NIH) Common Fund Program, Somatic Cell Genome Editing, through an award administered by the [Institute, Center or Office name] [(Institute, Center or Office abbreviation)] [(grant number)]; PIs: [PI names].” Manuscripts acknowledging SCGE funding should be a direct outcome of the supported work.
- C. If there is an NIH co-author, the NIH co-author must seek appropriate NIH approval.
- D. It is expected that the TCDC will be informed of all SCGE manuscript acceptances and provide the expected publication date.

### ***A.3.1 SCGE Consortium Manuscript Guidelines (e.g., Marker Paper):***

The SCGE Consortium, led by the Steering Committee, will develop a manuscript (or multiple manuscripts) that will describe, define and introduce the SCGE Consortium, or components of the Consortium, to the medical and scientific community.

1. Authors (First, Middle and Senior) will be determined by common agreement based upon the type, scope and site(s) of the project. The first author(s) will take primary responsibility for the manuscript. Given the nature of the SCGE Consortium’s collaborative work, shared first or last authors should be considered as an option.
2. The SCGE Consortium will be acknowledged at the end of the author list, as “Members of SCGE”.
3. Generally, it is expected that authors would make contributions to any or all of the following, including but not limited to the conception, design, acquisition and analysis of data, drafting of the manuscript, and editing and revision of the manuscript.
4. The TCDC will take a role in resolving all authorship disagreements for SCGE Consortium manuscripts on behalf of the SCGE Steering Committee and report to the Steering Committee any resolution or recommendations for resolution.

### ***A.4. Abstracts and Presentations:***

- A. Abstract submissions for consortium-wide activities require submission to the TCDC for review and presentation to the SCGE Coordinating and Steering Committees for review. Abstract submissions for Collaborative projects are encouraged to submit the abstract to the TCDC for review and reporting to the SCGE Steering Committee prior to submission. Abstracts prepared by an Individual project will not require review by the TCDC.

- B. All authors on abstracts and presentations must be made aware and confirm their authorship prior to submission or presentation.
- C. Abstracts and presentations should mention SCGE NIH SCGE Common Fund support as well as the appropriate SCGE grant number(s).
- D. To assist the SCGE TCDC in tracking SCGE Consortium member presentations, information (presenter, project PI(s), title, conference, location, date) for all invited and oral/poster presentations submitted to conferences should be submitted to the TCDC, [scge@mcw.edu](mailto:scge@mcw.edu)
- E. If there is an NIH co-author, the NIH co-author must seek the appropriate NIH approval.